Literature DB >> 7400205

Tumor inhibition by metallocenes: antitumor activity of titanocene dihalides (C5H5)2TiX2 (X=F, Cl, Br, I, NCS) and their application in buffered solutions as a method for suppressing drug-induced side effects.

P Köpf-Maier, B Hesse, R Voigtländer, H Köpf.   

Abstract

The antitumor activity of titanocene dihalides (C5H5)2TiX2 with X=F, Cl, Br, I, NCS is investigated against Ehrlich ascites tumor in CF 1 mice. Varying doses of the compounds are applied as single i.p. injections 24 h p.t.t. both in non-buffered (pH 1.4-3.9) and buffered (pH 4.2-5.9) solutions or suspensions, all of the substances achieving in optimum doses cure rates of 100% on day 120 p.t.t. This corresponds to I.L.S. values of 600-750% referred to the untreated controls. Some drug-induced side effects, especially the appearance of postperitonitic symptoms several weeks after i.p. application of higher doses of titanocene dihalides, are strikingly reduced by pH elevation in the injected drug solutions.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7400205     DOI: 10.1007/bf00411276

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  4 in total

1.  [Molybdocene dichloride as an antitumor agent (author's transl)].

Authors:  P Köpf-Maier; M Leitner; R Voigtländer; H Köpf
Journal:  Z Naturforsch C Biosci       Date:  1979-12

Review 2.  Platinum coordination complexes in cancer chemotherapy.

Authors:  B Rosenberg
Journal:  Naturwissenschaften       Date:  1973-09

3.  [Tumor inhibition by metallocenes: effect of titanocene, zirconocene, and hafnocene dichlorides on Ehrlich ascites tumor in mice (author's transl)].

Authors:  P Köpf-Maier; B Hesse; H Köpf
Journal:  J Cancer Res Clin Oncol       Date:  1980-01       Impact factor: 4.553

4.  The interaction of an anti-tumour platinum complex with DNA.

Authors:  I A Roos
Journal:  Chem Biol Interact       Date:  1977-01       Impact factor: 5.192

  4 in total
  15 in total

1.  Calcification of porcine and human cardiac valves: testing of various inhibitors for antimineralization.

Authors:  S Koutsopoulos; A Kontogeorgou; E Dalas; J Petroheilos
Journal:  J Mater Sci Mater Med       Date:  1998-07       Impact factor: 3.896

2.  Bioorganometallic Chemistry of Molybdenocene Dichloride and Its Derivatives.

Authors:  Enrique Meléndez
Journal:  J Organomet Chem       Date:  2012-02-06       Impact factor: 2.369

3.  Immunologic response to the treatment of Ehrlich ascites tumor with titanocene dichloride.

Authors:  P Köpf-Maier; A Hesse
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

4.  Development of necroses, virus activation and giant cell formation after treatment of Ehrlich ascites tumor with metallocene dichlorides.

Authors:  P Köpf-Maier
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

5.  Tumor inhibition by titanocene complexes: influence upon two xenografted human lung carcinomas.

Authors:  P Köpf-Maier
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

6.  Antitumor activity of ionic niobocene and molybdenocene complexes in high oxidation states.

Authors:  P Köpf-Maier; T Klapötke
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

7.  In Search for Titanocene Complexes with Improved Cytotoxic Activity: Synthesis, X-Ray Structure, and Spectroscopic Study of Bis(eta-cyclopentadienyl)difluorotitanium(IV).

Authors:  Elias Koleros; Theocharis C Stamatatos; Vassilis Psycharis; Catherine P Raptopoulou; Spyros P Perlepes; Nikolaos Klouras
Journal:  Bioinorg Chem Appl       Date:  2010-06-23       Impact factor: 7.778

8.  Antitumor properties of organometallic metallocene complexes of tin and germanium.

Authors:  P Köpf-Maier; C Janiak; H Schumann
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

9.  In vitro cell growth inhibition by metallocene dichlorides.

Authors:  P Köpf-Maier; W Wagner; H Köpf
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

10.  Ionic titanocene complexes: a new type of antitumor agent.

Authors:  P Köpf-Maier; E Neuse; T Klapötke; H Köpf
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.